Division of Surgery

Medicine & Life Sciences

1. Neoplasms 100%
2. Survival 55%
3. Neoplasm Metastasis 43%
4. Breast Neoplasms 39%
5. Therapeutics 36%
6. Ovarian Neoplasms 34%
7. Radiotherapy 34%
8. Drug Therapy 34%
9. Recurrence 33%
10. Melanoma 32%
11. Carcinoma 31%
12. Adenocarcinoma 23%
13. Urinary Bladder Neoplasms 22%
14. Squamous Cell Carcinoma 19%
15. Head and Neck Neoplasms 18%
16. Lymph Nodes 17%
17. Squamous Cell Carcinoma of Head and Neck 16%
18. Breast 16%
19. Sarcoma 16%
20. Prostatic Neoplasms 16%
21. Genes 16%
22. Radiation 16%
23. Mutation 15%
24. Endometrial Neoplasms 15%
25. Glioma 15%
26. Neck 15%
27. Renal Cell Carcinoma 15%
28. Growth 14%
29. Apoptosis 14%
30. Non-Small Cell Lung Carcinoma 14%
31. Pancreatic Neoplasms 14%
32. Lymph Node Excision 14%
33. Surgeons 13%
34. Confidence Intervals 13%
35. Cell Line 13%
36. Uterine Cervical Neoplasms 12%
37. Lung Neoplasms 12%
38. Mammaplasty 12%
39. Glioblastoma 12%
40. Head 11%
41. Colorectal Neoplasms 11%
42. Liver 11%
43. Ovarian Epithelial Carcinoma 10%
44. Biomarkers 10%
45. Neoadjuvant Therapy 10%
46. Clinical Trials 10%
47. Immunotherapy 10%
48. Oropharyngeal Neoplasms 10%
49. Sentinel Lymph Node 9%
50. Robotics 9%
51. Cisplatin 9%
52. Proteins 9%
53. Free Tissue Flaps 9%
54. Skin 8%
55. Biopsy 8%
56. Vascular Endothelial Growth Factor A 8%
57. Survival Rate 8%
58. Guidelines 8%
59. Incidence 8%
60. Odds Ratio 8%
61. Lung 8%
62. Esophageal Neoplasms 8%
63. Sentinel Lymph Node Biopsy 8%
64. Morbidity 8%
65. Heterografts 8%
66. ErbB Receptors 7%
67. Rectal Neoplasms 7%
68. Databases 7%
69. Mastectomy 7%
70. Progression-Free Survival 7%
71. Disease-Free Survival 7%
72. Adenoviridae 7%
73. MicroRNAs 7%
74. In Vitro Techniques 7%
75. Mortality 7%
76. Population 7%
77. Carcinogenesis 7%
78. Paclitaxel 7%
79. Colonic Neoplasms 7%
80. Quality of Life 7%
81. Cytoreduction Surgical Procedures 6%
82. Neoplasm Staging 6%
83. Chemoradiotherapy 6%
84. Platinum 6%
85. Systematic Reviews 6%
86. Segmental Mastectomy 6%
87. Radiosurgery 6%
88. Genetic Therapy 6%
89. Prostatectomy 6%
90. Thyroid Neoplasms 6%
91. T-Lymphocytes 6%
92. p53 Genes 6%
93. Gene Expression 6%
94. Stomach Neoplasms 6%
95. Single Nucleotide Polymorphism 6%
96. Brain Neoplasms 5%
97. Margins of Excision 5%
98. Safety 5%
99. Phenotype 5%